ADMA Biologics Shares Surge Following Third Quarter Earnings Beat
Shares of ADMA Biologics (ADMA) climbed more than 25% on Thursday, reaching their highest trading level since March. The surge follows the company's third-quarter financial results, which exceeded market expectations. The positive performance was primarily driven by strong sales of Asceniv, the company's intravenous immune globulin therapy. This growth highlights the increasing market demand for ADMA's plasma-derived product portfolio.
Tickers: $ADMA